Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Biological Standardization of Poa Pratensis Allergen Extract

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Laboratorios Leti, S.L.
ClinicalTrials.gov Identifier:
NCT01430117
First received: September 6, 2011
Last updated: August 20, 2012
Last verified: August 2012

September 6, 2011
August 20, 2012
October 2011
February 2012   (final data collection date for primary outcome measure)
Wheal size area (mm2) on the skin at the site of the puncture during the immediate phase. [ Time Frame: Test sites should be inspected and recorded 15-20 min after application ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01430117 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Biological Standardization of Poa Pratensis Allergen Extract
Biological Standardization of Poa Pratensis Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units

The objective of this study is to determine the biologic activity of a Poa pratensis allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).

This is an open, unblinded and non-randomized biological assay. The study design is a slight modification of the recommendations proposed by the Nordic Guidelines.

Four concentrations of Poa pratensis allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Allergy to Grass Pollen
Biological: Four different concentrations of Poa pratensis allergen extract, positive control and negative control
Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
Experimental: 1

Poa pratensis allergen extract at 4 different concentrations.

Positive control.

Negative control.

Intervention: Biological: Four different concentrations of Poa pratensis allergen extract, positive control and negative control
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
31
February 2012
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. A documented positive case history with inhalation allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) related to Poa pratensis.
  2. Subject has provided written informed consent, appropriately signed and dated by the subject (or legal representative, if applicable).
  3. Subject can be male or female of any race and ethnic group.
  4. Age > 18 years and < 50 years at the study inclusion day.
  5. Positive skin prick test with a standardized commercially available preparation of Poa pratensis allergen extract. The skin prick test will be considered positive if the test results in a wheal major diameter of at least 3 mm and at least the size of the positive control. Positive skin prick test results are valid if performed within one year prior to the inclusion of the subject in the study
  6. A positive test for specific IgE to Poa pratensis(CAP-RAST ≥ 2). IgE results are valid if performed within one year prior to the inclusion of the subject in the study.
  7. Allergic symptoms during the pollen season of Poa pratensis.
  8. Mean of the forearm major diameters of the wheals provoked by histamine dihydrochloride (10 mg/ml) ≥ 3 mm.

Exclusion Criteria:

  1. Immunotherapy in the past 5 years with an allergen preparation known to interfere with the allergen to be tested (e.g., grass group extracts).
  2. Use of drugs that may interfere with the skin reactions (e.g., antihistamines). See Appendix 1
  3. Treatment with any of the following medications: tricyclic or tetracyclic antidepressants, β-blockers or corticosteroids (> 10 mg/day of prednisone or equivalent).
  4. Pregnancy.
  5. Dermographism affecting the skin area at the test site at either study visit.
  6. Atopic dermatitis affecting the skin area at the test site at either study visit.
  7. Urticaria affecting the skin area at the test site at either study visit.
  8. Participation in another clinical trial within the last month.
  9. Subjects suffering from pathologies or conditions in which adrenalin is contraindicated (heart disease, severe hypertension,...)
Both
18 Years to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT01430117
6045-PR-PRI-183, 2010-023950-35
No
Laboratorios Leti, S.L.
Laboratorios Leti, S.L.
Not Provided
Study Chair: María José Gómez Laboratorios LETI, S.L.Unipersonal
Laboratorios Leti, S.L.
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP